Air-Q® SP Versus Air-Q® and I-gel

Laryngeal Masks Clinical Trial

Official title:

Comparison of the Air-Q® Self-Pressurizing (SP) Intubating Laryngeal Airway With the Air-Q® Intubating Laryngeal Airway and I-gel for Airway Maintenance in Adults Under General Anesthesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01592760
• Other study ID #: 2011-0805
• Status: Completed
• Phase: N/A
• First received: May 2, 2012
• Last updated: September 30, 2015
• Start date: May 2012
• Est. completion date: August 2014

Study information

• Verified date: December 2014
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The air-Q Self-Pressurizing Intubating Laryngeal Airway (aILA SP) is a modification of the air-Q Intubating Laryngeal Airway (aILA). Besides the i-gel, it is the only breathing tube that sits above the vocal cords that does not require inflation of a cuff with air. The purpose of this study is to compare the ability of the aILA-SP to maintain patency of a patient's airway during general anesthesia with that of the aILA and i-gel devices. As a measure of this ability, we hypothesized that the airway sealing pressures will be equal between the aILA-SP and aILA, but superior when comparing the aILA-SP to the i-gel (i-gel will be lower).

Description:

Laryngeal mask airways (LMAs) are a group of airway devices, alternatively referred to as supraglottic airways (SGAs), used in anesthesia that are positioned in the back of the throat (pharynx) above (supra) the glottis (windpipe opening) and the vocal cords. This is in contradistinction to a tracheal tube, which is an airway device that is placed through the vocal cords and extends to a position below the glottis (infraglottic) and resides in the trachea (windpipe). Since their first approval for use in the United States by the US Food and Drug Administration in the early 1990s, the application of SGAs has become more widespread. Initially, they were only used in anesthetized patients who were breathing on their own (i.e., spontaneously ventilating). This was, in large part, due to a relatively low airway seal pressure, the pressure with which the device seals against the throat, thereby, keeping the air pushed in by a breathing machine (ventilator) from getting into the stomach or leaking out around the device and out through the mouth - in either case, not going into the patient's lungs. The relatively low airway seal pressure (18 - 20 cmH2O) did not allow for the use of muscle relaxant (paralyzing) drugs and positive pressure ventilation. Successive generations of SGAs by a variety of manufacturers have overcome and continue to attempt to overcome limitations of earlier devices. In addition, accumulated clinical experience has made anesthesia providers more comfortable with their use. No SGA, however, is yet ideal, and incremental changes continue to appear to improve airway management and reduce airway morbidity (e.g., sore throat, jaw pain, etc.).

The air-Q® Intubating Laryngeal Airway (aILA, Mercury Medical, Clearwater, FL) is a newer, commercially-available, SGA designed for use as a primary airway and as an intubation conduit. It is available in polyvinyl chloride (PVC)-based, single use and silicone-based, reusable models. Information on its safety and effectiveness from a randomized, controlled trial in adults, undergoing general anesthesia, compared to that of the silicone-based, reusable aILA versus the LMA-Proseal™ (pLMA, North America, San Diego, CA), the current "gold standard" for SGA airway seal pressure, is available.

The air-Q® Self-Pressurizing (SP) Intubating Laryngeal Airway (aILA-SP, Mercury Medical, Clearwater, FL) is a commercially-available, modification of the silicone-based, reusable aILA. Its overall design is identical to the aILA, but incorporates a communication orifice between the air tube and cuff, which regulates airflow into and from the cuff during periods of positive pressure and spontaneous ventilation. As such, it incorporates a self-pressurizing cuff that does not require manual inflation. Such a cuff may be advantageous insofar as it dynamically adjusts its intra-cuff pressure and fit with the patient's pharyngeal and periglottic anatomy, which may lead to a reduction in airway morbidity, while still providing the high seal pressure afforded by the aILA design.

Lastly, the i-gel (Intersurgical Inc., Liverpool, NY) is a commercially-available SGA that uses a thermoplastic elastomer to create a non-inflating, anatomically-conforming, periglottic cuff. Studies have shown it to be an easily inserted, effective airway device with a lower incidence of sore throat and neck complaints. With exception to the aILA-SP, it is the only other commercially-available SGA that does not require cuff inflation.

To date, no reports are available on the clinical performance of the aILA-SP in relation to other SGAs. Thus, the primary purpose of this study is to compare the airway seal pressure (ASP) of the aILA-SP against the aILA and i-gel in adults undergoing general anesthesia. Airway seal pressure is the most common surrogate for ventilatory capacity used in SGA studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 225
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years;

• scheduled for an elective surgery or procedure; and

• general anesthesia with placement of a SGA planned.

Exclusion Criteria:

• < 18 years of age;

• non-English speaking;

• known or believed to be pregnant;

• prisoner;

• has impaired decision-making capacity;

• has symptomatic untreated gastroesophageal reflux;

• has had a prior esophagectomy;

• has a known or suspected hiatal hernia;

• has vomited within twenty-four hours of the surgery or procedure;

• has known oral pathology making a proper SGA fit unlikely; or

• has any condition for which the primary anesthesia care team deems intubation with a tracheal tube to be necessary.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Laryngeal Masks

Intervention

Device:
• air-Q SP
air-Q SP placement for airway maintenance.
• air-Q
air-Q placement for airway maintenance.
• i-gel
i-gel placement for airway maintenance.

Locations

Country	Name	City	State
United States	University of Wisconsin Hospital and Clinics	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

References & Publications (1)

Galgon RE, Schroeder KM, Han S, Andrei A, Joffe AM. The air-Q(®) intubating laryngeal airway vs the LMA-ProSeal(TM) : a prospective, randomised trial of airway seal pressure. Anaesthesia. 2011 Dec;66(12):1093-100. doi: 10.1111/j.1365-2044.2011.06863.x. Epub 2011 Aug 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Airway seal pressure after device placement	Airway seal pressure is defined as the pressure in cmH2O at which the needle of a manometer attached to the anesthesia circuit reaches equilibration, associated with an audible air leak from the subject's oropharynx or gastric insufflation, limited to a maximum pressure of 40 cmH2O. It is measured with the subject's head and neck in neutral position, the expiratory valve on the anesthesia machine closed, and the fresh gas flow set to five liters per minute.	Measured within 5 minutes after device placement/study initiation	No
Secondary	Device placement time	Device placement time is the time measured in seconds from when the study investigator picks up the airway device to confirmation of ventilation by the presence of an adequate end-tidal carbon dioxide tracing on the monitor.	Measured at device placement/study initiation	No
Secondary	Device placement success rate	Device placement success rate is defined as the proportion of devices successfully placed within three attempts at device placement.	Measured at device placement/study initiation	No
Secondary	Device ease of insertion	Device ease of insertion is graded as either easy, slightly difficult, difficult, or impossible.	Reported by the device operator at the time of device placement/study initiation	No
Secondary	Device position in relation to the vocal cords	Device position in relation to the vocal cords is assessed with a flexible fiberoptic camera and graded as follows: 1 = full view of the vocal cords, 2 = partial view of the vocal cords including the arytenoids, 3 = view of the epiglottis only, and 4 = other (device cuff, pharynx or other structures).	Measured within 5 minutes of device placement/study initiation	No
Secondary	Incidence of gastric insufflation	Gastric insufflation is present when audible air sounds are heard by stethoscope over the subject's epigastrium.	Measured within 5 minutes of device placement/study initiation	Yes
Secondary	Incidence of gastric aspiration	Gastric aspiration is present when gross gastric contents or bile is observed on or within the device or within the subject's oropharynx.	Measured between device placement/study initiation and device removal	Yes
Secondary	Incidence of oropharyngeal injury	Oropharyngeal injury is defined as a new lip, tongue, buccal, or pharyngeal abrasion or laceration or dental damage observed in the immediate recovery area after use of a study device.	Measured in the post-anesthesia care unit/recovery room within 15 minutes after device removal	Yes
Secondary	Incidence of device repositioning and/or replacement	Intra-operative device repositioning and/or replacement is defined as a need for intra-operative repositioning or replacement of the SGA due to excessive oropharyngeal air leak or airway obstruction, as evidenced by an obstructive pattern on the continuous end-tidal carbon dioxide monitor or audible pre-tracheal sounds, that leads to a decrease in oxygen saturation by pulse oximetry to less than 93%.	Measured between device placement/study initiation and device removal	No
Secondary	Hemodynamic measures at baseline	Systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, heart rate, and oxygen saturation at baseline	Measured 1 minute prior to induction of general anesthesia	Yes
Secondary	Hemodynamic measures at 1 minute after device placement	Systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, heart rate, and oxygen saturation 1 minute after device placement.	Measured 1 minute after device placement	Yes
Secondary	Hemodynamic measures at 2 minutes after device placement	Systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, heart rate, and oxygen saturation 2 minutes after device placement.	Measured 2 minutes after device placement	Yes
Secondary	Hemodynamic measures at 3 minutes after device placement	Systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, heart rate, and oxygen saturation 3 minutes after device placement.	Measured 3 minutes after device placement	Yes
Secondary	Hemodynamic measures at 4 minutes after device placement	Systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, heart rate, and oxygen saturation 4 minutes after device placement.	Measured 4 minutes after device placement	Yes
Secondary	Hemodynamic measures at 5 minutes after device placement	Systolic blood pressure, diastolic blood pressure, mean arterial blood pressure, heart rate, and oxygen saturation 5 minutes after device placement.	Measured 5 minutes after device placement	Yes
Secondary	Overall clinical usefulness	Excellent, good, fair, or inadequate. Scale defined by clinical measures and observations.	Reported by the device operator at the time of device removal	No
Secondary	Oropharyngolaryngeal morbidity at discharge	Perioperative oropharyngolaryngeal morbidity is assessed by the subject's response to standardized questions regarding oropharyngeal complaints.	Measured prior to discharge from phase II of the post-anesthesia care unit/recovery room	Yes
Secondary	Oropharyngolaryngeal morbidity at 24 hours post-operatively	Perioperative oropharyngolaryngeal morbidity is assessed by the subject's response to standardized questions regarding oropharyngeal complaints.	Measured at 24 hours after device placement/study initiation	Yes